Clinical Trial Update: Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the combination of atomoxetine and OROS methylphenidate for treating ADHD in children and adolescents aged 6 to 17; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)
• OROS-Methylphenidate (methylphenidate, osmotic release formulation)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: ADHD, Attention Deficit Hyperactivity Disorder | Phase 4 | Status: COMPLETED | Results posted: 2010-05-10